Experts Highlight Their Biggest Takeaways from the 2023 SOHO Annual Meeting

At the 2023 SOHO Annual Meeting in Houston, Texas, experts presented on the latest emerging data, changing treatment approaches, and next stages of research across a variety of hematologic malignancies. Alongside broader presentations, attendees also had the opportunity to meet with experts in smaller groups for more nuanced discussions about the latest trends in different areas and how they approach the treatment of various malignancies within clinical practice. 

In interviews with OncLive^®, key opinion leaders from across the hematologic oncology realm shared their biggest takeaways from the 2023 SOHO Annual Meeting.

• Harry Erba, MD, PhD, a professor of medicine, an investigator in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine, director of the Leukemia Program and director of Phase I Development in Hematologic Malignancies at Duke Cancer Institute.
• Yi Lin, MD, PhD, a hematologist and oncologist in the Department of Hematology and a member of the CAR T-Cell Therapy Program at Mayo Clinic.
• Tycel Phillips, MD, MPH, an associate clinical professor in the Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, at City of Hope.
• Stephen M. Ansell, MD, PhD, a professor of medicine, interim chair of the Department of Oncology, chair and consultant of the Division of Hematology, Department of Internal Medicine, and chair of Faculty Development and Recruitment at Mayo Clinic.

Erba highlights some of the key developments and emerging data from across the myelodysplastic syndrome and acute myeloid leukemia spaces. Lin points to presentations on CAR T-cell therapies, bispecific antibodies, and novel immunotherapies under investigation in multiple myeloma.

Philips explains that meetings such as the SOHO Annual Meeting allow for clinicians to share opinions on different data and treatment approaches in practice. Ansell concludes by detailing the emergence of immunotherapy agents and how they could be utilized in different sequences or combinations for patients with lymphoma.